CA3177377A1 - Compositions and methods for treating pulmonary edema or lung inflammation - Google Patents

Compositions and methods for treating pulmonary edema or lung inflammation

Info

Publication number
CA3177377A1
CA3177377A1 CA3177377A CA3177377A CA3177377A1 CA 3177377 A1 CA3177377 A1 CA 3177377A1 CA 3177377 A CA3177377 A CA 3177377A CA 3177377 A CA3177377 A CA 3177377A CA 3177377 A1 CA3177377 A1 CA 3177377A1
Authority
CA
Canada
Prior art keywords
dose
lung
hours
serum
hyperoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177377A
Other languages
English (en)
French (fr)
Inventor
David H. Ingbar
Timothy P. Rich
Robert J. Schumacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of CA3177377A1 publication Critical patent/CA3177377A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • G01N2800/125Adult respiratory distress syndrome
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3177377A 2020-03-27 2021-03-26 Compositions and methods for treating pulmonary edema or lung inflammation Pending CA3177377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000939P 2020-03-27 2020-03-27
US63/000,939 2020-03-27
PCT/US2021/024345 WO2021195488A1 (en) 2020-03-27 2021-03-26 Compositions and methods for treating pulmonary edema or lung inflammation

Publications (1)

Publication Number Publication Date
CA3177377A1 true CA3177377A1 (en) 2021-09-30

Family

ID=77892642

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177377A Pending CA3177377A1 (en) 2020-03-27 2021-03-26 Compositions and methods for treating pulmonary edema or lung inflammation

Country Status (7)

Country Link
US (1) US12569459B2 (https=)
EP (1) EP4126104A4 (https=)
JP (1) JP2023520770A (https=)
CN (1) CN115551569A (https=)
CA (1) CA3177377A1 (https=)
MX (1) MX2022011821A (https=)
WO (1) WO2021195488A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024778A1 (en) * 2023-07-27 2025-01-30 Regents Of The University Of Minnesota Medical treatment system and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716877B2 (en) 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US8309080B2 (en) 2007-12-06 2012-11-13 Naidu Lp Metallo-protein and tocotrienol (MP-T3) compositions and uses thereof
US8304401B2 (en) 2008-09-02 2012-11-06 Trustees Of Dartmouth College Compositions and methods for decreasing type III deiodinase activity to modulate adiposity and blood glucose levels
WO2010124372A1 (en) * 2009-04-29 2010-11-04 Genomedx Biosciences, Inc. Systems and methods for expression-based classification of thyroid tissue
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
US9913819B2 (en) 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
CN107041879A (zh) 2017-04-01 2017-08-15 深圳市润佳通科技有限公司 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防肺部疾病的药物中的应用
MX2020007971A (es) 2018-01-31 2020-09-09 Univ Minnesota Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
WO2019178023A1 (en) 2018-03-12 2019-09-19 Yale University Methods of Treating or Preventing Acute Respiratory Distress Syndrome

Also Published As

Publication number Publication date
JP2023520770A (ja) 2023-05-19
EP4126104A4 (en) 2024-04-17
US20230147865A1 (en) 2023-05-11
MX2022011821A (es) 2022-10-10
EP4126104A1 (en) 2023-02-08
CN115551569A (zh) 2022-12-30
US12569459B2 (en) 2026-03-10
WO2021195488A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US11883528B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
ES2399279T3 (es) Formulaciones de tobramicina para el tratamiento de infecciones endobronquiales
Alothman et al. Bronchial constriction and inhaled colistin in cystic fibrosis
US6702998B2 (en) Methods and devices for treating lung dysfunction
US20100330061A1 (en) Methods and Devices for Treating Lung Dysfunction
AU2002211222A1 (en) Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis
WO2002032418A1 (en) Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
Vendrell et al. Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis
Wagener et al. Anesthetic concerns in patients presenting with renal failure
US20250082715A1 (en) Compositions and methods for treatment of acute lung injury
van ‘t Veen et al. Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity
US20220265775A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
US12569459B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
ES3009563T3 (en) Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels
WO2015002818A1 (en) Treating or preventing nephrogenic diabetes insipidus
HK40087339A (zh) 用於治疗肺水肿或肺炎的组合物和方法
HK40046684A (en) Compositions and methods for treating pulmonary edema or lung inflammation
Multz Vasopressin dysregulation and hyponatremia in hospitalized patients
Narasimhan et al. New and investigational treatments in cystic fibrosis
RU2817906C2 (ru) Композиции и способы лечения острого повреждения легких
Kappeler et al. Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improve Tolerability

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250324

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250414

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250516